source
- Moderna and Merck report success for personalized mRNA vaccine in late-stage melanoma trialModerna and Merck announced that their personalized mRNA cancer vaccine succeeded in a late-stage melanoma study. The vaccine, called intismeran, was evaluated in a randomized Phase 3 trial, the fi…
- BioNTech appoints Sobi head Guido Oelkers as new CEO to steer oncology shiftBioNTech announced that Guido Oelkers, who has led the rare‑disease focused Swedish company Sobi since 2017, will become its next chief executive officer. Oelkers is slated to take over the role b…